

67. Brenda J. Underwood, Richmond, Virginia, Court of Federal Claims No: 20–0104V
68. Dennis Vivians, Bethesda, Maryland, Court of Federal Claims No: 20–0105V
69. Wesley Faske, Houston, Texas, Court of Federal Claims No: 20–0106V
70. Elissa DiPasquale, Commack, New York, Court of Federal Claims No: 20–0108V
71. Eva Gordon, Dallas, Texas, Court of Federal Claims No: 20–0109V
72. Tina Schaum-Hoey, Baltimore, Maryland, Court of Federal Claims No: 20–0110V
73. Camila Wagner, Lone Tree, Colorado, Court of Federal Claims No: 20–0111V
74. Angela Bulan Bogue, Youngsville, North Carolina, Court of Federal Claims No: 20–0112V
75. Angela Bulan Bogue, Youngsville, North Carolina, Court of Federal Claims No: 20–0113V
76. Teresa Washington-Jenkins, Lancaster, Pennsylvania, Court of Federal Claims No: 20–0114V

[FR Doc. 2020–03980 Filed 2–26–20; 8:45 am]

BILLING CODE 4165–15–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Committee on Vital and Health Statistics: Meeting

Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) announces the following advisory committee meeting.

**NAME:** National Committee on Vital and Health Statistics (NCVHS), Full Committee Meeting.

**DATES AND TIMES:**

Tuesday, March 24, 2020: 9:00 a.m.–5:30 p.m.

Wednesday, March 25, 2020: 8:30 a.m.–3:00 p.m.

**PLACE:** U.S. Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue SW, Rm. 505A, Washington, DC 20201.

**STATUS:** Open.

**PURPOSE:** At the March 24–25, 2020 meeting, the Committee will welcome four new NCVHS members, review and discuss a recent request received from the Designated Standard Maintenance Organizations (DSMO), receive briefings from HHS officials to inform discussion of the Committee’s workplan, and hold discussions on several health data policy topics.

The Subcommittee on Standards will lead the Committee in a discussion of the most recent change request received from the DSMO taking into consideration input from stakeholders regarding costs and benefits of implementing the most recent version of the National Council for Prescription

drug Programs (NCPDP) pharmacy standard (NCPDP F6).

The Health Insurance Portability and Accountability Act (HIPAA) of 1996, as amended,<sup>1</sup> gives statutory authority to the Secretary of Health & Human Services (HHS) to promulgate regulations adopting standards, code sets, and identifiers to support the exchange of electronic health information between covered entities. The standards are for retail pharmacy and medical transactions. New versions of the adopted standards may be brought forward to NCVHS by the standards development organizations (SDOs) or through the DSMO after completion of a consensus-based review and evaluation process.

The Committee’s intent is to understand the changes in version F6 and whether there are substantive changes which need to be evaluated that would significantly change the Committee’s recommendation to HHS submitted in 2018. There is no change to the Batch Standard Implementation Guide Version 15 and the Subrogation Implementation Guide for Batch Standard Version 10, which were included in the May 2018 NCVHS recommendation. The Committee requests input and comments from the public in advance of this meeting to inform its deliberations about the benefits or costs of changing to this new version. The change request letter and change log are available for review at <https://ncvhs.hhs.gov/Letter-to-NCVHS-DSMO-Change-Request-January-21-2020>. Please submit comments specific to the impact of the change from version F2 to F6 to [NCVHSmal@cdc.gov](mailto:NCVHSmal@cdc.gov) by close of business Friday, March 13, 2020.

The Subcommittee on Standards will introduce a new project scoping statement for its work on convergence of administrative and clinical data standards using the prior authorization transaction as a use-case. The Subcommittee will also provide an update on its activities in collaboration with the Office of the National Coordinator for Health Information Technology (ONC) and the Health Information Technology Advisory Committee (HITAC) regarding the opportunity for burden reduction through convergence of administrative and clinical data standards using the prior authorization transaction as a use-case.

The Subcommittee on Privacy, Confidentiality and Security will lead a discussion of the full Committee to

<sup>1</sup> Along with Section 1104 (c) of the Affordable Care Act.

assess priority areas for focus and activity. HHS agencies will brief the Committee regarding recent and ongoing work to inform the Committee’s discussion of the 2020 workplan.

There will be a public comment period on both meeting days. The times and topics are subject to change. Please refer to the posted agenda for any updates.

**CONTACT PERSON FOR MORE INFORMATION:**

Substantive program information may be obtained from Rebecca Hines, MHS, Executive Secretary, NCVHS, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Hyattsville, Maryland 20782, telephone (301) 458–4715. Summaries of meetings and a roster of Committee members are available on the home page of the NCVHS website: [www.ncvhs.hhs.gov](http://www.ncvhs.hhs.gov), where further information including an agenda and instructions to access the broadcast of the meeting will also be posted.

Should you require reasonable accommodation, please contact the CDC Office of Equal Employment Opportunity on (770) 488–3210 as soon as possible.

Dated: February 20, 2020.

**Sharon Arnold,**

*Associate Deputy Assistant Secretary for Planning and Evaluation, Science and Data Policy, Office of the Assistant Secretary for Planning and Evaluation.*

[FR Doc. 2020–03981 Filed 2–26–20; 8:45 am]

BILLING CODE 4150–05–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special

Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01).

*Date:* March 23, 2020.

*Time:* 9:00 a.m. to 1:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD 20892 (Virtual Meeting).

*Contact Person:* Tara Capece, Ph.D., Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD 20852, 240-191-4281, [capecet2@niaid.nih.gov](mailto:capecet2@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: February 21, 2020.

**Tyeshia M. Roberson,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020-03938 Filed 2-26-20; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of the Director, National Institutes of Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Advisory Committee to the Director, National Institutes of Health.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Advisory Committee to the Director, National Institutes of Health.

*Date:* April 23, 2020.

*Time:* 11:00 a.m. to 12:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Building 1, One Center Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Gretchen Wood, Staff Assistant, National Institutes of Health, Office of the Director, One Center Drive,

Building 1, Room 126, Bethesda, MD 20892, 301-496-4272, [Woodgs@od.nih.gov](mailto:Woodgs@od.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: February 21, 2020.

**Natasha M. Copeland,**

*Deputy Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020-03940 Filed 2-26-20; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel PAR Panel; Cancer Health Disparities.

*Date:* March 23-24, 2020.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Ola Mae Zack Howard, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4192, MSC 7806, Bethesda, MD 20892, 301-451-4467, [howardz@mail.nih.gov](mailto:howardz@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Small Business; Cancer Drug Development and Therapeutics.

*Date:* March 23-24, 2020.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Canopy by Hilton, 940 Rose Avenue, North Bethesda, MD 20852.

*Contact Person:* Lilia Topol, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6192, MSC 7804, Bethesda, MD 20892, 301-451-0131, [ltopol@mail.nih.gov](mailto:ltopol@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel PAR Panel; Alzheimer Disease Research.

*Date:* March 23, 2020.

*Time:* 10:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Dr., Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Andrew Loudon, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3137, Bethesda, MD 20817, 301-435-1985, [loudenar@csr.nih.gov](mailto:loudenar@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel PAR Panel; Mammalian Models for Translation Research.

*Date:* March 23, 2020.

*Time:* 11:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Dr., Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Malaya Chatterjee, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6192, MSC 7804, Bethesda, MD 20892, 301-806-2515, [chatterm@csr.nih.gov](mailto:chatterm@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Perception and Cognition Research to Inform Cancer Image Interpretation.

*Date:* March 23, 2020.

*Time:* 1:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Dr., Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Devon Rene Brost Oskvig, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3172, Bethesda, MD 20892, [brostd@csr.nih.gov](mailto:brostd@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 21, 2020.

**Tyeshia M. Roberson,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020-03941 Filed 2-26-20; 8:45 am]

**BILLING CODE 4140-01-P**